论文部分内容阅读
只有极少数医保目录内没有替代品的创新产品需要进行药物经济学评价,基于经济性评价,成本效果分析以及预算谈判,谈判成功后医保予以报销。日前,由医保部门主导的第一轮创新药谈判已经结束,这代表着我国在探索建立医保药品谈判准入机制的道路上迈出了重要一步。但是在这个过程中还有很多值得思考和理清的问题。谈判的对象参加医保谈判的产品应该是专利、独家、费用高且不可替代的产品。创新药申请进入医保目录评审之前要进行
Only a handful of innovative products with no substitutes in the Medicare catalog need to be evaluated in pharmacoeconomics, based on economic evaluations, cost-effectiveness analyzes, and budget negotiations, which are reimbursed after successful negotiation. Recently, the first round of innovator drug talks led by the health insurance sector has come to an end, which represents an important step taken by our country on exploring the establishment of a negotiating mechanism for Medicare drug negotiations. However, there are still many issues worth thinking about and clarifying in this process. The object of the negotiations Products participating in the Medicare negotiations should be patented, exclusive, expensive and irreplaceable products. Innovative drugs to apply before entering the medical insurance directory review to be carried out